BCR and chronic myelogenous leukemia, BCR-ABL1 positive: We report two cases of CML patients carrying the p230 transcript, who achieved fast and deep complete molecular response (CMR), defined as the absence of detectable BCR-ABL transcripts by RQ-PCR, after frontline treatment with nilotinib.